Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Blue Origin launches New Glenn rocket on company's first NASA-scale science mission - 2Canada's Serene Lakeside Mountain Village Is A Breathtaking Oasis For Outdoor Adventure
- 3Avoid This Common Mistake When Planning Sightseeing Activities For Your Trip To Italy
- 4The most effective method to Decisively Use Open Record Rewards
- 5Heavy rain, floods kill at least 45 people in Afghanistan, Pakistan
- Two Indonesian UN peacekeepers killed in explosion in Lebanon
- Benedict Cumberbatch takes on something even Sherlock can’t solve: male grief
- Air travelers face higher ticket prices as Iran war drives up oil prices
- Instructions to Decide whether a Fender bender Legal counselor is Required for Your Particular Case
- Social Skylines d: A Survey of \Inside and out Social Experiences\ Language Learning Book
- British Columbia's Secret Lakeside Town With Hot Springs Is 'An Oasis Of Arts, Culture And Relaxation'
- Defense Minister Katz moves to extend IDF service to 36 months
- Figure out How to Pick the Right Toothbrush for You
- Jennifer Lawrence and Josh Hutcherson to reprise their roles for new 'Hunger Games' movie 'Sunrise on the Reaping'
